ERBB2 and breast carcinoma: Mittendorf et al also reported the phase II trial evaluating GP2 (a HER2‐derived, HLA‐A2+ restricted peptide) + GM‐CSF (granulocyte‐macrophage colony‐stimulating factor) setting to breast cancer patients to prevent recurrence.